Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
AstraZeneca
Moodys
Colorcon
Mallinckrodt

Last Updated: May 26, 2022

Intersect Ent Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for INTERSECT ENT INC, and when can generic versions of INTERSECT ENT INC drugs launch?

INTERSECT ENT INC has one approved drug.

There are thirteen US patents protecting INTERSECT ENT INC drugs.

There are forty-seven patent family members on INTERSECT ENT INC drugs in twelve countries and two supplementary protection certificates in two countries.

Summary for Intersect Ent Inc
International Patents:47
US Patents:13
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Intersect Ent Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No 8,025,635 See Plans and Pricing Y See Plans and Pricing
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No 7,951,133 See Plans and Pricing See Plans and Pricing
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No 7,713,255 See Plans and Pricing See Plans and Pricing
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No 8,763,222 See Plans and Pricing Y See Plans and Pricing
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No 7,544,192 See Plans and Pricing See Plans and Pricing
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No 8,109,918 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for Intersect Ent Inc Drugs

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2014151963 See Plans and Pricing
China 102573981 See Plans and Pricing
Japan 5247428 See Plans and Pricing
European Patent Office 2298317 See Plans and Pricing
Singapore 11201507476T See Plans and Pricing
European Patent Office 2754463 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Intersect Ent Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0112669 96C0002 Belgium See Plans and Pricing PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
0548114 SPC/GB97/064 United Kingdom See Plans and Pricing PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Johnson and Johnson
AstraZeneca
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.